

# BIBLIOGRAPHY

Joshua Michael Hare, M.D., F.A.C.C., F.A.H.A.

## AGING

### Articles:

1. Golpanian S, El-Khorazaty J, Mendizabal A, DiFede DL, Suncion V, Karantalis V, Fishman JE, Ghersin E, Balkan W, **Hare JM**. Effect of Aging on human Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy Patients. *J Am Coll Cardiol*. 2015 Jan 20;65(2):125-32. doi: 10.1016/j.jacc.2014.10.040.
2. Golpanian S, DiFede DL, Pujol MV, Lowery MH, Levis-Dusseau S, Goldstein BJ, Schulman IH, Longsomboon B, Wolf A, Khan A, Heldman AW, Goldschmidt-Clermont PJ, **Hare JM**. Rationale and design of the allogeneic human mesenchymal stem cells (hMSC) in patients with aging frailty via intravenous delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty. *Oncotarget*. 2016 Mar 15;7(11):11899-912. doi: 10.18632/oncotarget.7727.
3. Golpanian S, DiFede DL, Khan A, Schulman IH, Landin AM, Tompkins BA, Heldman AW, Miki R, Goldstein BJ, Mushtaq M, Levis-Dusseau S, Byrnes JJ, Lowery M, Natsumeda M, Delgado C, Saltzman R, Vidro-Casiano M, Pujol MV, Da Fonseca M, Oliva AA Jr, Green G, Premer C, Medina A, Valasaki K, Florea V, Anderson E, El-Khorazaty J, Mendizabal A, Goldschmidt-Clermont PJ, **Hare JM**. Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty. *J Gerontol A Biol Sci Med Sci*. 2017 Apr 21. Doi: 10.1093/gerona/glx056 [Epub ahead of print]
4. Tompkins B, DiFede DL, Khan A, Landin AM, Schulman I, Pujol M, Heldman A, Miki R, Goldschmidt-Clermont P, Goldstein B, Mushtaq M, Levis-Dusseau S, Byrnes J, Lowery M, Natsumeda M, Delgado C, Saltzman R, Vidro-Casiano M, Da Fonseca M, Golpanian S, Premer C, Medina A, Valasaki K, Florea V, Anderson E, El-Khorazaty J, Mendizabal A, Green G, Oliva A, **Hare JM**. Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A phase II randomized, double-blind, placebo controlled clinical trial. *J Gerontol A Biol Sci Med Sci*. 2017 Oct 12;72(11):1513-1522. doi: 10.1093/gerona/glx137.

### Book Chapter:

1. Tompkins BA, Landin AM, Florea V, Natsumeda M, Tieger AC, Balkan W, Schulman IH, **Hare JM**. Allogeneic Mesenchymal Stem Cells as a Treatment for Aging Frailty. *Frailty and Sarcopenia*. Published online 2017 Jul 17. doi:10.1093/gerona/glx137, PMID: 28977399, In book: *Frailty and Sarcopenia - Onset, Development and Clinical Challenges*.

## REGENERATIVE MEDICINE

### Articles:

1. Schulman IH, Suncion V, Karantalis V, Balkan W, **Hare JM**; Cardiovascular Cell Therapy Research Network. Clinical research skills development program in cell-based regenerative medicine. *Stem Cells Transl Med*. 2015 Feb;4(2):118-22. doi: 10.5966/sctm.2014-0144. Epub 2014 Dec 29.

### Reviews:

1. Zimmet J, **Hare JM**. Emerging role for bone marrow derived mesenchymal stem cells in myocardial regenerative therapy. *Basic Res in Cardiol* 2005; 100:471-481.
2. Bhatia R, **Hare JM**. Mesenchymal Stem Cells: Future Source for Reparative Medicine. *Congestive Heart Failure* 2005;11:87-91

### Editorials:

1. Karantalis V, Schulman IH, Balkan W, **Hare JM**. Allogeneic cell therapy: a new paradigm in therapeutics. *Circ Res*. 2015 Jan2;116(1):12-5.doi:10.1161/CIRCRESAHA. 1114.305495. No abstracts available. PMID: 25552688.
2. Cao Y, Balkan W, **Hare JM**. S-nitrosylation and MSC-mediated body composition. *Oncotarget*. 2015 Oct 6;6(30):28517-8. doi: 10.18632/oncotarget.5672.

### Book Chapter:

1. Schulman IH, Balkan W, Saltzman R, DaFonseca D, Caceres LV, Delgado C, Pujol MV, Ramdas KN, Tovar Jairo J, Vidro-Casiano M, **Hare JM**. Unique Aspects of the Design of Phase I/II Clinical Trials of Stem Cell Therapy. Submitted: July 18th 2017Reviewed: December 6th 2017Published: June 6th 2018 [in press]

## MUSCULOSKELETAL ORTHOPEDICS

### Articles:

1. Cao Y, Gomes SA, Rangel EB, Paulino EC, Fonseca TL, Li J, Teixeira MB, Gouveia CH, Bianco AC, Kapiloff MS, Balkan W, **Hare JM**. S-nitrosoglutathione reductase-dependent PPAR $\gamma$  denitrosylation participates in MSC-derived adipogenesis and osteogenesis. *J Clin Invest*. 2015 Apr 1;125(4):1679-91. doi: 10.1172/JCI73780. Epub 2015 Mar 23.
2. Vance DD, Kanashiro-Takeuchi RM, Ajibade D, Takeuchi L, Rangel EB, Hamilton K, Balkan W, Rosenberg A, **Hare JM**, Kaplan LD, Lesniak B. Allogeneic Mesenchymal Stem Cells with or without Platelet Rich Plasma in the Treatment of Medical Collateral Ligament Injury in Rats: An Experimental Laboratory Study. *J Orth Rhe Sp Med*. 2015 Oct 20. [in press]

### Reviews:

1. Bashir J, Sherman A, Lee H, Kaplan L, **Hare JM**. Mesenchymal stem cell therapies in the treatment of musculoskeletal diseases. *PM R*. 2014 Jan; 6(1):61-9. doi: 10.1016/j.pmrj.2013.05.007. [PubMed – in process]

2. Ajibade, DA, Vance DD, **Hare JM**, Kaplan LD, Lesniak, BP. Emerging Applications of Stem Cell and Regenerative Medicine to Sports Injuries. *Orthopaedic Journal of Sports Medicine*, 2(2), 2014 Feb 6. doi: 10.1177/2325967113519935

## CARDIOVASCULAR

### Articles:

1. Kraitchman D, Heldman AW, Atalar E, Pittinger M, Martin B, **Hare JM**, Bulte J. In vivo Magnetic Resonance Imaging of Mesenchymal Stem Cells in Myocardial Infarction. *Circulation* 2003;107:2290-2293.
2. Amado LC, Saliaris AP, Schuleri KH, St John M, Xie J, Cattaneo S, Durand DJ, Fitton T, Jin Qiang Kuang JQ, Stewart G, Lehrke S, Baumgartner W, Martin BJ, Heldman AW, **Hare JM**. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. *Proc Natl Acad Sci U S A*. 2005 Aug 9;102(32):11474-9. Epub 2005 Aug 1
3. Lehrke S, Mazhari R, Durand DJ, Zheng M, Bedja D, Zimmet J, Schuleri KH, Chi AS, Gabrielson KL, **Hare JM**. Aging impairs the beneficial effect of granulocyte-colony stimulating factor and stem cell factor on post myocardial infarction remodeling. *Circulation Research* 2006; 99:553-560.
4. Amado LC, Schuleri KH, Saliaris A P, Boyle AJ, Helm R, Oskouei B, Centola M, Eneboe V, Young R, Lima JAC, Lardo AC, Heldman AW, **Hare JM**. Multi-modality non-invasive imaging demonstrates in-vivo cardiac regeneration following mesenchymal stem cell therapy. *J Amer Coll Cardiology*, 2006;48:2116-2124.
5. Mazhari R, **Hare JM**. Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. *Nat Clin Pract Cardiovasc Med*, 2007;4 Suppl 1:S21-S26.
6. Schuleri K, Boyle A, Centola, M, Amado L, Evers R, Zimmet J, Evers K, Hannon K, Scorpio D, **Hare JM**, Lardo A. Novel Use of the Adult Göttingen Minipig as a Chronic Heart Failure Model post Myocardial Infarction: Focus on Cardiovascular Imaging and Regenerative Therapies. *Comparative Medicine*; 2008;58:568-79.
7. **Hare JM**, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. *J Am Coll Cardiol*, 2009 Dec 8;54(24):2277-86. doi: 10.1016/j.jacc.2009.06.055.
8. Schuleri KH, Feigenbaum GS, Centola M, Weiss ES, Zimmet JM, Turney J, Kellner J, Zviman MM, Hatzistergos KE, Detrick B, Conte JV, McNiece I, Steenbergen C, Lardo AC, **Hare JM**. Autologous mesenchymal stem cells produce reverse remodeling in chronic ischemic cardiomyopathy. *Eur Heart J*. 2009 Nov; 30(22):2722-32. Epub 2009 Jul 8.
9. Cires RS, Patel H, Tamariz LJ, **Hare JM**, Zambrano JP. Effect of Granulocyte-Colony Stimulating Factor on Systolic Function of Oncology Patients. *J Am Coll Cardiol* 2011; 57:516-7.
10. Hatzistergos KE, Quevedo HC, Oskouei BN, Hu Q, Feigenbaum GS, Margitich IS, Mazhari R, Boyle AJ, Zambrano JP, Rodriguez JE, Dulce RA, Pattany PM, Valdes D, Revilla C, Heldman

- AW, McNiece I, **Hare JM**. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. *Circ Res*. 2010 Oct 1; 107(7):913-22. Epub 2010 Jul 29.
11. Trachtenberg B, Velazquez D, Williams A, McNiece I, Fishman J, Nguyen K, Rouy D, Altman D, Schwarz R, Mendizabal A, Zambrano JP, Heldman AW, **Hare JM**. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: a randomized, double-blinded, placebo controlled study of safety and efficacy. *Am Heart J*. 2011;161:487-93.
  12. Williams, AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, Mendizabal AM, Pattany PM, Lopera GA, Fishman J, Zambrano JP, Heldman AW, **Hare JM**. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling. *Circulation Research*, 2011; 108:792-6. Epub 2011 Mar 17.
  13. Oskouei BN, Lamirault G, Joseph C, Treuer AV, Landa S, DaSilva J, Hatzistergos K, Dauer M, Balkan W, McNiece I, **Hare JM**: Increased potency of human cardiac stem cells compared to bone marrow mesenchymal stem cells in cardiac repair. *Stem Cells-Transl Med*. 2012 Feb;1(2):116-24. doi: 10.5966/sctm.2011-0015. Epub 2012 Feb 7.
  14. McCall FC, Telukuntla KS, Karantalis V, Suncion VY, Heldman AW, Mushtaq M, Williams AR, **Hare JM**. Myocardial infarction and intramyocardial injection models in swine and the implications for mechanistic translational research and regulatory approval. *Nature Protocols* 2012, Jul 12; 7(8):1479-96.
  15. **Hare JM**, Fishman JE, Gerstenblith G, Velazquez DLD, Zambrano JP, Suncion VY, Tracy M, Gershin E, Jonhston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW. Randomized Comparison of Allogeneic vs. Autologous Bone Marrow Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients with Ischemic Cardiomyopathy, Results of the Poseidon trial. *JAMA*. 2012 Dec 12; 308(22): 2369-79.
  16. Williams AR, Hatzistergos KE, Addicott B, McCall F, Carvalho D, Suncion V, Morales AR, Da Silva J, Sussman MA, Heldman AW, **Hare JM**. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. *Circulation* 2013 Jan 15; 127(2):213-23. doi: 10.1161/CIRCULATIONAHA.112.131110. Epub 2012 Dec 5.
  17. **Hare JM**, Bolli R, Cooke JP, Gordon DJ, Henry TD, Perin EC, March KL, Murphy MP, Pepine CJ, Simari RD, Skarlatos SI, Traverse JH, Willerson JT, Szady AD, Taylor DA, Vojvodic RW, Yang PC, Moyé LA; Cardiovascular Cell Therapy Research Network (CCTRN). Phase II Clinical Research Design in Cardiology: Learning the Right Lessons Too Well: Observations and Recommendations From the Cardiovascular Cell Therapy Research Network (CCTRN). *Circulation*. 2013 Apr 16; 127(15):1630-5. doi: 10.1161/CIRCULATIONAHA.112.000779. No abstract available.
  18. Williams AR, Suncion VY, McCall F, Guerra D, Mather J, Zambrano JP, Heldman AW, **Hare JM**. Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. *J Am Heart Assoc*. 2013 May 17;2(3):e000140. doi: 10.1161/JAHA.113.000140.

19. Heldman AW, DiFede D, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK, Ghersin E, Soto V, Lopera G, Miki R, Willens H, Hendel R, Mitrani R, Pattany P, Feigenbaum G, Oskouei B, Byrnes J, Lowery MH, Sierra J, Pujol MV, Delgado C, Gonzalez PJ, Rodriguez JE, Bagno LL, Rouy D, Altman P, Foo CW, da Silva J, Anderson E, Schwarz R, Mendizabal A, **Hare JM**. Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy: The TAC-HFT Randomized Trial. *JAMA*. 2014 Jan 1;311(1):62-73. doi: 10.1001/jama.2013.282909.
20. Suncion VY, Ghersin E, Fishman J, Zambrano JP, Karantalis V, Mandel NS, Nelson KH, Gerstenblith G, Difede DL, Breton E, Sitammagari KK, Schulman IH, Taldone S, Williams AR, Sanina C, Johnston P, Brinker JA, Altman PA, Mushtaq M, Trachtenberg B, Mendizabal A, Tracy M, Da Silva J, McNiece I, Lardo A, George RT, **Hare JM**, Heldman A. Does Transendocardial Injection of Mesenchymal Stem Cells Improve Myocardial Function Locally or Globally? An Analysis From the POSEIDON Randomized Trial. *Circ Res*. 2014 Apr 11;114(8):1292-301. doi: 10.1161/CIRCRESAHA.114.302854. Epub 2014 Jan 21.
21. Karantalis V, Difede DL, Gerstenblith G, Pham SM, Symes JF, Zambrano JP, Fishman J, Pattany PM, McNiece I, Conte JV, Schulman SP, Wu KC, Shah A, Breton E, Davis-Sproul J, Schwarz RP, Feigenbaum G, Mushtaq M, Suncion VY, Lardo A, Borrello I, Mendizabal A, Karas TZ, Byrnes J, Lowery MH, Heldman A, **Hare JM**. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. *Circ Res*. 2014 Apr 11;114(8):1302-10. doi: 10.1161/CIRCRESAHA.114.303180. Epub 2014 Feb 24.
22. Simari RD, Pepine CJ, Traverse JH, Henry TD, Bolli R, Spoon DB, Yeh E, **Hare JM**, Schulman IH, Anderson RD, Lambert C, Sayre SL, Taylor DA, Ebert RF, Moyé LA. Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network. *Circ Res*. 2014 May 9;114(10):1564-8. doi: 10.1161/CIRCRESAHA.114.303720. Review.
23. Mushtaq M, DiFede DL, Golpanian S, Khan A, Gomes S, Mendizabal A, Heldman AW, **Hare JM**. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. *J Cardiovasc Transl Res*. 2014 Dec;7(9):769-80. doi: 10.1007/s12265-014-9594-0. Epub 2014 Oct 30.
24. Premer C, Blum A, Bellio MA, Schulman IH, Hurwitz BE, Parker M, Dermarkarian CR, DiFede DL, Balkan W, Khan A, **Hare JM**. Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor Cells. *EBioMedicine*. 2015 Mar 28;2(5):467-75. doi: 10.1016/j.ebiom.2015.03.020. eCollection 2015 May.
25. 182. Hatzistergos KE, Paulino EC, Dulce RA, Takeuchi LM, Bellio MA, Kulandavelu S, Cao Y, Balkan W, Kanashiro-Takeuchi RM, **Hare JM**. S-Nitrosoglutathione Reductase Deficiency Enhances the Proliferative Expansion of Adult Heart Progenitors and Myocytes Post Myocardial Infarction. *J Am Heart Assoc*. 2015 Jul 15;4(7). pii: e001974. doi: 10.1161/JAHA.115.001974.

26. White IA, Gordon J, Balkan W, **Hare JM**. Sympathetic Reinnervation is Required for Mammalian Cardiac Regeneration. *Circ. Res.* 2015 Sep 14. pii: CIRCRESAHA.115.307465. [Epub ahead of print]
27. Hatzistergos KE, Takeuchi LM, Saur D, Seidler B, Dymecki SM, Mai JJ, White IA, Balkan W, Kanashiro-Takeuchi RM, Schally AV, **Hare JM**. cKit+ cardiac progenitors of neural crest origin. *Proc Natl Acad Sci U S A.* 2015 Oct 20;112(42):13051-6. doi: 10.1073/pnas.1517201112. Epub 2015 Oct 5.
28. Karantalis V, Suncion-Loescher VY, Bagno L, Golpanian S, Wolf A, Sanina C, Premer C, Kanelidis AJ, McCall F, Wang B, Balkan W, Rodriguez J, Rosado M, Morales A, Hatzistergos KE, Natsumeda M, Margitich I, Schulman IH, Gomes SA, Mushtaq M, DiFede DL, Fishman JE, Pattany P, Zambrano JP, Heldman AW, **Hare JM**. Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy. *J Am Coll Cardiol.* 2015 Nov 3;66(18):1990-9. doi: 10.1016/j.jacc.2015.08.879.
29. Golpanian S, Schulman IH, Ebert RF, Heldman AW, DiFede DL, Yang PC, Wu JC, Bolli R, Perin EC, Moye L, Simari RD, Wolf A, **Hare JM**, Cardiovascular Cell Therapy Research Network. Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease. *Stem Cells Transl Med.* 2016 Feb;5(2):186-91. doi: 10.5966/sctm.2015-0101. Epub 2015 Dec 18.
30. Hatzistergos KE, Saur D, Seidler B, Balkan W, Breton M, Valasaki K, Takeuchi LM, Landin AM, Khan A, **Hare JM**. Stimulatory Effects of Mesenchymal Stem Cells on cKit+ Cardiac Stem Cells Are Mediated by SDF1/CXCR4 and SCF/cKit Signaling Pathways. *Circ Res.* 2016 Sep 30;119(8):921-30. doi: 10.1161/CIRCRESAHA.116.309281.
31. Bellio MA, Rodrigues CO, Landin AM, Hatzistergos KE, Florea V, Valasaki K, Khan A, **Hare JM**, Schulman IH. Physiologic and Hypoxic Oxygen Concentration Differentially Regulate Human c-Kit+ Cardiac Stem Cell Proliferation and Migration. *Am J Physiol Heart Circ Physiol.* 2016 Dec 1;311(6):H1509-H1519. doi: 10.1152/ajpheart.00449.2016.
32. Kulandavelu S, Karantalis V, Fritsch J, Hatzistergos KE, Loescher VY, McCall F, Wang B, Bagno LL, Golpanian S, Wolf A, Grenet J, Williams A, Kupin A, Rosenfeld A, Mohsin S, Sussman M, Morales A, Balkan W, **Hare JM**. Pim1 Kinase Overexpression Enhances ckit+ Cardiac Stem Cell Cardiac Repair Following Myocardial Infarction in Swine. *J Am Coll Cardiol.* 2016 Dec 6;68(22):2454-2464. doi: 10.1016/j.jacc.2016.09.925.
33. Kanelidis A, Premer C, Lopez JG, Balkan W, **Hare JM**. Route of Delivery Modulates the Efficacy of Mesenchymal Stem Cell Therapy for Myocardial Infarction: A Meta-Analysis of Preclinical Studies and Clinical Trials. *Circ Res.* 2017 Mar 31;120(7):1139-1150. doi: 10.1161/CIRCRESAHA.116.309819. Epub 2016 Dec 28.
34. **Hare JM**, DiFede DL, Castellanos AM, Florea V, Landin AM, El-Khorazaty J, Khan A, Mushtaq M, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Alfonso CE, Valasaki K, Pujol MV, Golpanian S, Ghersin E, Fishman JE, Pattany P, Gomes SA, Delgado C, Miki R, Abuzeid F, Vidro-Casiano M, Premer C, Medina A, Porras V, Hatzistergos KE, Anderson E, Mendizabal A, Mitrani R, Heldman AW. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. *J Am Coll Cardiol.* 2017 Feb 7;69(5):526-537. doi: 10.1016/j.jacc.2016.11.009.

35. Perin EC, Murphy MP, March KL, Bolli R, Loughran J, Yang PC, Leeper NJ, Dalman RL, Alexander J, Henry TD, Traverse JH, Pepine CJ, Anderson RD, Berceli S, Willerson JT, Muthupillai R, Gahremanpour A, Raveendran G, Velasquez O, **Hare JM**, Schulman IH, Kasi VS, Hiatt WR, Ambale-Venkatesh B, Lima JA, Taylor DA, Resende M, Gee AP, Durett AG, Bloom J, Richman S, G'Sell P, Williams S, Khan F, Ross EG, Santoso M, Goldman J, Leach D, Handberg E, Cheong B, Piece N, DiFede D, Bruhn-Ding B, Caldwell E, Bettencourt J, Lai D, Piller L, Simpson L, Cohen M, Sayre SL, MPH15, Vojvodic RW, Moyé L, Ebert RF, Simari RD, Hirsch AT, Cardiovascular Cell Therapy Research Network (CCTRN). Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). *Circulation*. 2017 Apr 11;135(15):1417-1428. doi: 10.1161/CIRCULATIONAHA.116.025707. Epub 2017 Feb 16.
36. Ramireddy A, Brodt CR, Mendizabal AM, DiFede DL, Healy C, Goyal V, Alansari Y, Coffey JO, Viles-Gonzalez JF, Heldman AW, Goldberger J, Myerburg RJ, **Hare JM**, Mitrani RD. Effects of Transendocardial Stem Cell Injection on Ventricular Proarrhythmia in patients with Ischemic Cardiomyopathy: Results from the POSEIDON and TAC-HFT Trials. *Stem Cells Transl Med*. 2017 May;6(5). doi: 10.1002/sctm.16-0328. Epub 2017 Mar 2.
37. Shahrivari M, Wise E, Resende M, Shuster JJ, Zhang J, Bolli R, Cooke JP, **Hare JM**, Henry TD, Khan A, Taylor DA, Traverse JH, Yang PC, Pepine CJ, Cogle CR, Cardiovascular Cell Therapy Research Network (CCTRN). Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1 $\beta$ - and IL-6-Related Impairment of Bone Marrow Function. *Circ Res*. 2017 Jun 9;120(12):1947-1957. doi: 10.1161/CIRCRESAHA.116.309947. Epub 2017 May 10.
38. Mayourian J, Cashman TJ, Ceholski DK, Johnson BV, Sachs D, Kaji DA, Sahoo S, **Hare JM**, Hajjar RJ, Sobie EA, Costa KD. Experimental and Computational Insight into Human Mesenchymal Stem Cell Paracrine Signaling and Heterocellular Coupling Effects on Cardiac Contractility and Arrhythmogenicity. *Circ Res*. 2017 Aug 4;121(4):411-423. doi: 10.1161/CIRCRESAHA.117.310796. Epub 2017 Jun 22.
39. Yanamandala M, Zhu W, Garry DJ, Kamp T, **Hare JM**, Jun H, Yoon Y, Bursac N, Prabhu SD, Dorn GW, Bolli R, Kitsis RN, Zhang J. Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering. *J Am Coll Cardio*. 2017 Aug 8;70(6):766-775. doi: 10.1016/j.jacc.2017.06.012. Review.
40. Eschenhagen T, Bolli R, Braun T, Field LJ, Fleischmann BK, Frisén J, Giacca M, **Hare JM**, Houser SR, Lee RT, Marbán E, Martin JF, Molkentin JD, Murry CE, Riley PR, Ruiz-Lozano P, Sadek HA, Sussman MA, Hill JA. Cardiomyocyte Regeneration: A Consensus Statement. *Circulation*. 2017 Aug 15;136(7):680-686. doi: 10.1161/CIRCULATIONAHA.117.029343. Epub 2017 Jul 6. Review. No abstract available.
41. Bellio MA, Pinto MT, Florea V, Barrios PA, Taylor CN, Brown AB, Lamondin C, **Hare JM**, Schulman IH, Rodrigues CO. Hypoxic Stress Decreases c-Myc Protein Stability in Cardiac Progenitor Cells Inducing Quiescence and Compromising Their Proliferative and Vasculogenic Potential. *Sci Rep*. 2017 Aug 29;7(1):9702. doi: 10.1038/s41598-017-09813-x.
42. Fernandez-Aviles F, Sanz-Ruiz R, Climent AM, Badimon L, Bolli R, Charron D, Fuster V, Janssens S, Kastrup J, Kim H, Luscher TF, Martin JF, Menasche P, Simari RD, Stone GW, Terzic A, Willerson JT, Wu JC; TACTICS (Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes) Writing Group. Authors/Task Force Members. Chairpersons: Fernandez-Aviles F (Spain), Terzic A (USA); Basic Research Subcommittee: Badimon L (Spain),

Broughton K (USA), DiFede DL (USA), Dimmeler S (Germany), Madonna R (Italy), Penn MS (USA), Sussman MA (USA), Sluijter JPG (The Netherlands), Wollert KC (Germany); Translational Research Subcommittee: Balkan W (USA), Bolli R (USA), Chamuleau S (The Netherlands), Charron D (France), Fernandez-Santos ME (Spain), Fuster V (USA), Goliash G (Austria), Gyongyosi M (Austria), **Hare JM** (USA), Luscher TF (Switzerland), Tompkins BA (USA), Winkler J (Austria); Challenges of Cardiovascular Regenerative Medicine Subcommittee: Bayes-Genis A (Spain), Henry TD (USA), Taylor DA (USA); Tissue Engineering Subcommittee: Climent AM (Spain), Lerman A (USA), Pelacho B (Spain), Prosper F (Spain); Delivery, Navigation, Tracking and Assessment Subcommittee: Sanz-Ruiz R (Spain), Perin EC (USA), Pompilio G (Italy); Clinical Trials Subcommittee: Gersh B (USA), Bartunek J (Belgium), Duckers E (The Netherlands), Ferdinandy P (Hungary), Janssens S (Belgium), Losordo DW (USA), Sanchez PL (Spain), Sherman W (Belgium), Wojakowski W (Poland), Zeiher A (Germany), Kastrup J (Denmark), Roncalli J (France), Mathur A (UK); Regulatory and funding strategies subcommittee: Crea F (Italy), D'Amario D (Italy), Povsic TJ (USA), Traverse J (USA), Yla-Herttuala S (Finland). Global Position Paper on Cardiovascular Regenerative Medicine. Scientific Statement of the Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes (TACTICS) International Group for the Comprehensive Cardiovascular Application of Regenerative Medicinal Products. *Eur Heart J*. 2017 Sep 1;38(33):2532-2546. doi: 10.1093/eurheartj/ehx248. No abstract available.

43. Kaushal S, Wehman B, Pietris N, Naughton C, Bentzen SM, Bigham G; Mishra R, Sharma S, Vricella L, Everett A, Deatrck K, Huang S, Mehta , Ravekes W, Hibino N, Difede DL, Khan A, **Hare JM**. Study Design and Rationale for ELPIS: A Phase I/IIb Randomized Pilot Study Of Allogeneic Human Mesenchymal Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome. *Am Heart J Assoc*. 2017 Oct;192:48-56. doi: 10.1016/j.ahj.2017.06.009. Epub 2017 Jun 27.
44. Florea V, Rieger AC, Difede DL, El-Khorazaty J, Natsumeda M, Banerjee MN, Tompkins BA, Khan A, Schulman IH, Landin AM, Mushtaq M, Lowery MH, Byrnes J, Hendel RC, Cohen MG, Valasaki K, Pujol MV, Ghersin E, Miki R, Delgado C, Abuzeid FA, Vidro-Casiano M, Saltzman R, DaFonseca D, Caceres LV, Ramdas KN, Mendizabal A, Heldman AW, Mitrani RD, **Hare JM**. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients with Ischemic Cardiomyopathy (The TRIDENT Study). *Circ Res*. 2017 Nov 10;121(11):1279-1290. doi: 10.1161/CIRCRESAHA.117.311827. Epub 2017 Sep 18.
45. Natsumeda M, Florea V, Rieger AC, Tompkins BA, Banerjee MN, Golpanian S, Fritsch J, Landin AM, Kashikar ND, , Karantalis V, Loescher VY, Hatzistergos KE, Bagno L, Sanina C, Mushtaq M, Rodriguez J, Rosado M, Wolf A, Collon K, Vincent L, Kanelidis AJ, Schulman IH, Mitrani R, Heldman AW, Balkan W, **Hare JM**. A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration. *J Am Coll Cardiol*. 2017 Nov 14;70(20):2504-2515. doi: 10.1016/j.jacc.2017.09.036.
46. Tompkins BA, Rieger AC, Florea V, Natsumeda M, Banerjee MN, Nigh ED, Landin AM, Rodriguez GM, Hatzistergos KE, Schulman IH, **Hare JM**. Ischemic vs. Non-Ischemic Dilated Cardiomyopathy: a Comparative Study in Mesenchymal Stem Cell Therapy Efficacy. *J Am Heart Assoc*. 2018 Jan. [Revision under review]
47. Bolli R, **Hare JM**, Henry TD, Lenneman CG, March K, Miller K, Pepine CJ, Perin EC, Traverse J, Willerson JT, Yang P, Gee AP, Moyé L, Vojvodic R, Sayre SL, Bettencourt J, Cohen M, Ebert RF,



- Simari R for the Cardiovascular Cell Therapy Research Network (CCTRN). Rationale and Design of the SENECA (StEm cell iNjECTION in cAnCER survivors) Trial. *Am Heart J*. 2018 Feb. [In press]
48. Hatzistergos KE, Jiang Z, Valasaki K, Takeuchi LM, Balkan W, Atluri P, Saur D, Seidler B, Tsinoremas N, DiFede DL, **Hare JM**. Simulated Microgravity Impairs Cardiac Autonomic Neurogenesis from Neural Crest Cells. *Stem Cells Dev*. 2018 Mar 20. doi: 10.1089/scd.2017.0265. [Epub ahead of print]
  49. Mayourian J, Ceholski DK, Gorski PA, Mathiyalagan P, Murphy JF, **Hare JM**, Sahoo S, Hajjar RJ, Costa KD. Exosomal microRNA-21-5p Mediates Mesenchymal Stem Cell Paracrine Effects on Human Cardiac Tissue Contractility. *Circ Res*. 2018 Mar 30;122(7):933-944. doi: 10.1161/CIRCRESAHA.118.312420. Epub 2018 Feb 15.
  50. Bolli R, **Hare JM**, March K, Pepine CJ, Willerson JT, Perin EC, Yang P, Henry TD, Traverse J, Mitrani R, Khan A, Schulman I, Taylor D, DiFede DL, Lima J, Chugh A, Loughran J, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Ebert RF, Moye L, Simari R. Rationale and Design of the CONCERT-HF (Combination Of meseNchymal and c-kit+ Cardiac stEm cells as Regenerative Therapy for Heart Failure) Trial. *Circ Res*. 2018 Apr. [In press]

### **Reviews:**

1. Boyle AJ, Schulman SP, **Hare JM**. Stem cell therapy for cardiac repair: Ready for the next step. *Circulation*, 2006; 114:339-352
2. Mazhari R, **Hare JM**. Advances in cell-based therapy for structural heart disease. *Prog Cardiovasc Dis*. 2007;49:387-95.
3. Ramos G, **Hare JM**. Cardiac Cell-Based Therapy: Cell types and Mechanisms of Actions. *Transplantation* 2007;16(9):951-61.
4. Young K, **Hare JM**. Stem Cells in Cardiopulmonary Development: Implications for novel approaches to therapy for Pediatric Cardiopulmonary Disease. *Progress in Pediatric Cardiology* 2008;25; 37-49
5. Chapparo S, **Hare JM**. Cardiac regeneration and stem cell therapy. *Current Opinion in Organ Transplantation* 2008;13:536-42.
6. Kanashiro-Takeuchi RM, Schulman IH, **Hare JM**. Pharmacologic and genetic studies to enhance cell therapy for cardiac regeneration. *J Mol Cell Cardiol*. 2011 Oct;51(4):619-25. Epub 2011 May 30.
7. Williams A, **Hare JM**. Mesenchymal Stem Cells: Biology, Patho-Physiology, Translational findings and therapeutic implications for cardiovascular disease. *Circ Res*. 2011 Sep 30;109(8):923-40.
8. Suncion VY, Schulman IH, Hare JM. The Role of Clinical Trials in Deciphering Mechanisms of Action of Cardiac Cell-Based Therapy. *Stem Cells Translational Medicine*, 1:29-35, 2012
9. Blum A, Balkan W, **Hare JM**. Advances in cell-based therapy for peripheral vascular disease. *Atherosclerosis*. 2012 Aug; 223(2): 269-77. doi: 10.1016/j.atherosclerosis.2012.03.017. Epub 2012 Mar 23
10. Karantalis V, Balkan W, Schulman IH, Hatzistergos KE, **Hare JM**. Cell-Based Therapy for Prevention and Reversal of Myocardial Remodeling. *Am J Physiol Heart Circ Physiol*. 2012 Aug 1; 303(3): H256-70. doi: 10.1152/ajpheart.00221.2012. Epub 2012 May 25.

11. Mazhari R, **Hare JM**, Translational Findings from Cardiovascular Stem Cell Research. *Trends Cardiovasc Med*. 2012 Jan; 22(1): 1-6.
12. Schulman IH, **Hare JM**. Key developments in stem cell therapy in cardiology. *Regen Med*. 2012 Nov; 7(6 Suppl):17-24.
13. Selem SM, Kaushal S, **Hare JM**. Stem cell therapy for pediatric dilated cardiomyopathy. *Curr Cardiol Rep*. 2013 Jun;15(6):369. doi: 10.1007/s11886-013-0369-z.
14. Karantalis V, Balkan W, Schulman IH, Hatzistergos KE, **Hare JM**. Cell-based therapy for prevention and reversal of myocardial remodeling. *Am J Physiol Heart Circ Physiol*. 2012 Aug 1; 303(3):H256-70. Epub 2012 May 25. Review.
15. Telukuntla KS, Suncion VY, Schulman IH, **Hare JM**. The advancing field of cell-based therapy: insights and lessons from clinical trials. *J Am Heart Assoc*. 2013 Oct 10;2(5):e000338. doi: 10.1161/JAHA.113.000338. Review. No abstract available. PMID: 24113326
16. Karantalis V, **Hare JM**. Use of Mesenchymal Stem Cells for Therapy of Cardiac Disease. *Circ Res*. 2015 Apr 10;116(8):1413-1430. Review.
17. Golpanian S, Wolf A, Chatzistergos KE, **Hare JM**. Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy and Engineered Heart Tissue. *Physiol Rev*. 2016 Jul;96(3):1127-68. doi: 10.1152/physrev.00019.2015. Review.
18. Tompkins BA, Balkan W, Winkler J, Gyöngyösi M, Goliash G, Fernández-Avilés F, **Hare JM**. Preclinical Studies of Stem Cell Therapy for Heart Disease. *Circ Res*. 2018 Mar 30;122(7):1006-1020. doi: 10.1161/CIRCRESAHA.117.312486. Review.

### **Editorials:**

1. Abraham R, **Hare JM**. Is skeletal myoblast transplantation proarrhythmic? The jury is still out. *Heart Rhythm* 2006; 3:462-463.
2. Heldman A, **Hare JM**. Cell therapy for myocardial infarction: Special delivery. [\*J Mol Cell Cardiol\*](#). 2008;44:473-6
3. Feigenbaum GS, Lemberg L, **Hare JM**. Tracking cell fate with non-invasive imaging. *J Am Coll Cardiol*. 2009; 54:1627-8
4. Heldman AW, Zambrano JP, **Hare JM**. Cardiac Stem Cell Therapy: Where are we in 2011. *J Am Coll Cardiol* 2011;57:466-468
5. Mushtaq M, Oskouei B, **Hare JM**. Stem Cells for Heart Disease: To genetically modify or not that is the question. *Circ Res*. 2011;108:398-401
6. **Hare JM**. Bone marrow therapy for myocardial infarction. *JAMA* 2011 in press.
7. Friedwald VE, **Hare JM**, Miller LW, Walpole HT Jr, Willerson JT, Roberts WC. The Editor's Roundtable: Advances in Stem Cell Therapy Treatment of Cardiovascular Disease. Associate Editor, *The American Journal of Cardiology*, and Clinical Professor of Medicine, University of Texas-Houston Health Science Center, Houston, Texas. [Pub Med- in press]
8. Premer C, **Hare JM**. Can endothelial progenitor cells treat patients with refractory angina? *Circ Res*. 2014 Nov 7;115(11):904-7. doi: 10.1161/CIRCRESAHA.114.305284. No abstract available.
9. **Hare JM**, Sanina C. Bone Marrow Mononuclear Cell Therapy and Granulocyte Colony-

Stimulating Factor for Acute Myocardial Infarction: Is it Time to Reconsider? *J Am Coll Cardiol*. 2015 Jun 9;65(22):2383-7. doi: 10.1016/j.jacc.2015.03.571. No abstract available.

10. Sanina C, **Hare JM**. Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We With Cardiac Cell- Based Therapy? *Circ Res*. 2015 Jul 17;117(3):229-33. doi: 10.1161/CIRCRESAHA.117.306306.
11. Hatzistergos KE, **Hare JM**. Cell Therapy: Targeting Endogenous Repair Versus Remuscularization. *Circ Res*. 2015 Sep 25;117(8):659-61. doi: 10.1161/CIRCRESAHA.115.307346. No abstract available.
12. Tompkins BA, Balkan W, **Hare JM**. Perspectives on the Evolution of Stem Cell Therapy for Heart Failure. *EBioMedicine*. 2015 Nov 26;2(12):1838-9. doi: 10.1016/j.ebiom.2015.11.043. eCollection 2015 Dec. No abstract available. PMID: 26844249
13. Hatzistergos KE, **Hare JM**. Murine Models Demonstrate Distinct Vasculogenic and Cardiomyogenic cKit+ Lineages in the Heart. *Circ Res*. 2016 Feb 5;118(3):382-7. doi: 10.1161/CIRCRESAHA.115.308061
14. Florea V, Balkan W, Schulman IH, **Hare JM**. Cell Therapy Augments Myocardial Perfusion and Improves Quality of Life in Patients With Refractory Angina. *Circ Res*. 2016 Mar 18;118(6):911-5. doi: 10.1161/CIRCRESAHA.116.308409. No abstract available.
15. Bellio MA, Balkan W, **Hare JM**, Schulman IH. Is the regulation of SIRT1 by miRNA-34a the key to mesenchymal stem cell survival? *Ann Transl Med*. 2016 Jun;4(12):243. doi: 10.21037/atm.2016.05.45. No abstract available.
16. Landin AM, **Hare JM**. The quest for a successful cell-based therapeutic approach for heart failure. *Eur Heart J*. 2017 Mar 1;38(9):661-664. doi: 10.1093/eurheartj/ehw626. No abstract available.
17. Tompkins BA, Natsumeda M, Balkan W, **Hare JM**. What is the Future of Cell-Based Therapy for Acute Myocardial Infarction. *Circ Res*. 2017 Jan 20;120(2):252-255. doi: 10.1161/CIRCRESAHA.116.310340. No abstract available.
18. Kulandavelu S, Balkan W, **Hare JM**. Next-Generation Stem Cell Therapy: Genetically Modified Mesenchymal Stem Cells for Cardiac Repair : Editorial to: "Mesenchymal Stem Cells with eNOS Over-Expression Enhance Cardiac Repair in Rats with Myocardial Infarction" by Leilei Chen et al. *Cardiovasc Drugs Ther*. 2017 Feb;31(1):5-7. doi: 10.1007/s10557-017-6714-5. No abstract available.
19. Tompkins BA, Rieger AC, Florea V, Banerjee MN, **Hare JM**. New insights into cell-based therapy for heart failure from the CHART-1 study. *Eur J Heart Fail*. 2017 Nov;19(11):1530-1533. doi: 10.1002/ejhf.955. Epub 2017 Sep 25. No abstract available.

## LUNG

### Articles:

1. Young KC, Torres E, Hatzistergos KE, Hehre D, Suquihara C, **Hare JM**. Inhibition of the SDF-1/CXCR4 axis attenuates neonatal hypoxia-induced pulmonary hypertension. *Circ Res* 2009; 104:1293-301. Epub 5/7/2009.
2. Ramachandran S, Suguihara C, Drummond S, Chatzistergos K, Klim J, Torres E, Huang J, Hehre D, Rodrigues CO, McNiece IK, **Hare JM**, Young KC. Bone Marrow-Derived c-kit Positive Cells

Attenuate Neonatal Hyperoxia-Induced Lung Injury. *Cell Transplant*. 2013 May 22. doi: 10.3727/096368913X667736. [Epub ahead of print]

3. Matthay MA, Anversa P, Bhattacharya J, Burnett BK, Chapman HA, **Hare JM**, Hei DJ, Hoffman AM, Kourembanas S, McKenna DH, Ortiz LA, Ott HC, Tente W, Thébaud B, Trapnell BC, Weiss DJ, Yuan JX, Blaisdell CJ. Cell Therapy for Lung Diseases: Report from an NIH-NHLBI Workshop November 13-14, 2012. *Am J Respir Crit Care Med*. 2013 Aug 1;188(3):370-5. doi: 10.1164/rccm.201303-0522WS. Review
4. Miranda LF, Rodrigues CO, Ramachandran S, Torres E, Huang J, Klim J, Hehre D, McNiece I, **Hare JM**, Sugihara CY, Young KC. Stem cell factor improves lung recovery in rats following neonatal hyperoxia-induced lung injury. *Pediatr Res*. 2013 Dec;74(6):682-8. doi: 10.1038/pr.2013.165. Epub 2013 Oct 23. PMID: 24153399.
5. Young KC, Torres E, Hehre D, Wu S, Sugihara C, **Hare JM**. Antagonism of stem cell factor/c-kit signaling attenuates neonatal chronic hypoxia-induced pulmonary vascular remodeling. *Pediatr Res*. 2015 Dec 24. doi: 10.1038/pr.2015.275. [Epub ahead of print]
6. Glassberg M, Minkiewicz J, Toonkel R, Simonet E, Rubio G, DiFede D, Shafazand S, Khan A, Pujol M, LaRussa V, Lancaster L, Rosen G, Fishman J, Mageto Y, Mendizabal A, **Hare JM**. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis intravenous delivery (AETHER): a phase I, safety, clinical trial. *Chest*. 2016 Nov 24. pii: S0012-3692(16)62462-5. doi: 10.1016/j.chest.2016.10.061.[Epub ahead of print]
7. Reiter J, Drummond S, Sammour I, Huang J, Florea V, Dornas P, **Hare JM**, Rodrigues CO, Young KC. Stromal derived factor-1 mediates the lung regenerative effects of mesenchymal stem cells in a rodent model of bronchopulmonary dysplasia. *Respir Res*. 2017 Jul 12;18(1):137. doi: 10.1186/s12931-017-0620-z.

### **Reviews:**

1. Toonkel RL, **Hare JM**, Matthay MA, Glassberg MK. Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. *Am J Respir Crit Care Med*. 2013 Jul 15;188(2):133-40. doi: 10.1164/rccm.201207-1204PP.

## **CANCER**

### **Editorials:**

1. Hatzistergos KE, Blum A, Ince T, Grichnik JM, **Hare JM**. What is the oncologic risk of stem cell therapy for heart disease? *Circ Res*. 2011;108:1300-3.

## **SENSORINEURAL**

### **Articles:**

1. Goldstein, B. J., **Hare, JM**, Lieberman, S. & Casiano, R. Adult human nasal mesenchymal stem cells have an unexpected broad anatomic distribution. *International Forum Allergy Rhinology Int Forum Allergy Rhinol*. 2013 Jul;3(7):550-5. doi: 10.1002/alr.21153. Epub 2013 Feb 19
2. Bas E, VanDeWater TR, Lumbreras V, Rajguru S, Goss G, **Hare JM** and Goldstein BJ. Adult human nasal mesenchymal-like stem cells restore cochlear spiral ganglion neurons after

experimental lesion. *Stem Cells Dev.* 2014 Mar 1;23(5):502-14. doi: 10.1089/scd.2013.0274. Epub 2013 Dec 4. PMID: 24172073

3. Goldstein BJ, Goss G, Hatzistergos KE, Rangel EB, Seidler B, Saur D, **Hare JM**. Adult c-Kit (+) progenitor cells are necessary for maintenance and regeneration of olfactory neurons. *J Comp Neurol.* 2015 Jan 1;523(1):15-31. doi: 10.1002/cne.23653. Epub 2014 Aug 25.
4. Goss GM, Chaudhari N, **Hare JM**, Nwojo R, Seidler B, Saur D, Goldstein BJ. Differentiation potential of individual olfactory c-Kit+ progenitors determined via multicolor lineage tracing. *Dev Neurobiol.* 2015 May 27. doi: 10.1002/dneu.22310. [Epub ahead of print]
5. Goldstein BJ, Goss GM, Choi R, Saur D, Seidler B, **Hare JM**, Chaudhari N. Contribution of Polycomb group proteins to olfactory basal stem cell self-renewal in a novel c-KIT+ culture model and in vivo. *Development.* 2016 Dec 1;143(23):4394-4404.
6. Chen X, Wang S, Xu H, Pereira JD, Hatzistergos KE, Saur D, Seidler B, **Hare JM**, Perrella MA, Yin ZQ, Liu X. Evidence for a retinal progenitor cell in the postnatal and adult mouse. *Stem Cell Res.* 2017 Aug;23:20-32. doi: 10.1016/j.scr.2017.06.010. Epub 2017 Jul 6.
7. Kurtenbach S, Ding W, Goss GM, **Hare JM**, Goldstein BJ, Shehadeh LA. Differential expression of microRNAs among cell populations in the regenerating adult mouse olfactory epithelium. *PLoS One.* 2017 Nov 6;12(11):e0187576. doi: 10.1371/journal.pone.0187576. eCollection 2017.

## KIDNEYS

### Articles:

1. Rangel EB, Gomes SA, Dulce RA, Premer C, Rodrigues CO, Kanashiro-Takeuchi RM, Oskouei B, Carvalho DA, Ruiz P, Reiser J, **Hare JM**. C-Kit+ Cells Isolated from Developing Kidneys are a Novel Population of Stem Cells with Regenerative Potential. *Stem Cells.* 2013 Aug;31(8):1644-56. doi: 10.1002/stem.1412.
2. Rangel EB, **Hare JM**, Gomes SA. Therapeutic potential of kidney c-Kit cells Kidney-derived c-Kit+ cells possess regenerative potential. *Stem Cells-Transl Med.* 2018 Jan. [Epub ahead of print]
3. Gomes SA, **Hare JM**, Rangel EB. Kidney-Derived c-Kit+ Cells Possess Regenerative Potential. *Stem Cells Transl Med.* 2018 Apr;7(4):317-324. doi: 10.1002/sctm.17-0232.

### Reviews:

1. Mollura DJ, **Hare JM**, Rabb H. Stem-cell therapy for renal diseases. *Am J Kidney Dis.* 2003;42:891-905.

## BRAIN

### Articles:

1. Yavagal DR, Lin B, Raval AP, Garza PS, Dong C, Zhao W, Rangel E, McNiece I, Rundek T, Sacco RL, Perez-Pinzon MA, **Hare JM**. Efficacy and Dose-Dependent Safety of Intra-Arterial Delivery of Mesenchymal Stem Cells in a Rodent Stroke Model. *PLOS ONE.* 2014 May 7;9(5):e93735. doi: 10.1371/journal.pone.0093735. eCollection 2014.

2. Santamaria AJ, Benavides FD, DiFede DL, Khan A, Pujol MV, Dietrich D, Marttos A, Green BA, **Hare JM**, Guest JD. Clinical and neurophysiological changes after targeted intrathecal injections of bone marrow stromal cells in a C3 tetraplegic subject. *J Neurotrauma*. 2018 April. [In press]